
The combination of breast cancer drugs Tykerb and Xeloda are effective at slowing the progression of metastatic breast cancer after the drug Herceptin fails -- but the drug duo is only effective at extending the lives of patients for a few months, according to the results of a recent international clinical trial.
The trial, led by Charles E. Geyer, M.D., of Allegheny General Hospital, Pittsburgh and published in the December 28 issue of
The New England Journal of Medicine, focused on 324 women whose breast cancer had spread to other organs. The women had already been treated with Herceptin for a median of 42-44 weeks -- and then half received Xeloda chemotherapy and half received both Xeloda and Tykerb.
Women who received the drug combination had more than a 50 percent delay in disease progression. Their cancer spread after a median 8.4 months, compared to 4.4 months for women who received only Xeloda.
Targeted drugs Herceptin and Tykerb are major advances in the fight against breast cancer -- for the 20 percent of diagnosed women with the aggressive HER2 positive disease -- and they are also quite expensive. While some say they are worth every penny if they offer a cure, others question the cost if they only delay the disease progression for a few months. Such was the case in this study.
Perhaps the greatest potential for these agents is for use before breast cancer spreads, when they may improve the chance for a cure.